SecBot SecBot
8-K ·Filed May 26, 2026

TCRT

Alaunos Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed5mo ago SEC0001193125-26-238237
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The preclinical data is scientifically interesting but irrelevant to the stock's near-term trajectory, the company will likely need to raise capital within weeks or face a cash crisis. Expect dilutive financing (equity or convertible) that will pressure the stock. The 0% analyst bullish consensus and tiny market cap ($59M) amplify downside risk.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.45
T+0 close · May 26, 2026 · via day close
Latest settled
−23.27%
T+60 · $1.88
Vs SPY
−25.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $2.45entry
  2. T+1 · 6mo ago +14.69%α +14.68% · $2.81
  3. T+5 · 6mo ago +17.14%α +16.06% · $2.87
  4. T+20 · 5mo ago −11.84%α −9.89% · $2.16
  5. T+60 · 3mo ago −23.27%α −25.99% · $1.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral non-hormonal obesity candidate, showing multi-axis metabolic improvements in diet-induced obese mouse studies. However, the company disclosed it had only ~$0.354 million cash as of March 31, 2026, with runway extending only into Q2 2026, making the financing risk acute and the preclinical data largely academic without capital to advance the program.

Key Facts

  • ALN1003 showed body weight reductions up to -30.5% (p<0.0001) in high-dose DIO mouse study, but with dose aversion and dehydration confounders
  • Cash and cash equivalents were approximately $0.354 million as of March 31, 2026
  • Cash runway extends only into the second quarter of 2026
  • Company intends to pursue additional financing to support continued operations
  • ALN1003 has not been evaluated in human clinical trials; safety and efficacy in humans not established
  • Non-GLP preclinical studies with limited sample sizes and qualitative pathology scoring
  • Mild reversible hypolocomotion observed in ~50% of doses in one study; dose aversion and dehydration in the other

Financial Impact

Cash balance of ~$0.354M with runway through Q2 2026, imminent financing need; no revenue or earnings reported

cashfinancing risk

Risk Factors

  • Imminent need for dilutive financing with only ~$0.354M cash runway through Q2 2026
  • Preclinical data may not translate to humans; non-GLP study limitations
  • Tolerability signals (hypolocomotion, dose aversion) could complicate IND-enabling work
  • Crowded obesity market with well-capitalized competitors

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-238237
Document: tcrt-ex99_1.htm0001193125-26-238237
Document: 0001193125-26-238237-index-headers.html0001193125-26-238237
Document: 0001193125-26-238237-index.html0001193125-26-238237
Document: 0001193125-26-238237.txt0001193125-26-238237

Track record

14 reports on TCRT

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +26.36% at T+60 after the Apr 15, 2026 report. 3 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago S-3 Bearish 6/10 Entry $1.63 Now $1.60 +1.84% settles Dec 14
  2. Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
  4. Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  5. Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  6. Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
  7. Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
  8. Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
  9. Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026